Sopharma AD

Sopharma AD maintains a debt-to-equity ratio of 0.63, indicating a moderate reliance on debt financing, and a current ratio of 1.3, suggesting adequate short-term liquidity to cover its obligations. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints. The company's free cash flow of BGN 64.3 million supports operational flexibility, though capital expenditures of BGN -142.8 million suggest ongoing investment in infrastructure or production capacity. In terms of profitability, Sopharma AD reports a return on equity (ROE) of 14.03% and a return on assets (ROA) of 6.42%, both of which exceed the typical thresholds for the pharmaceutical and drug retailing industries. These metrics indicate strong capital efficiency and asset utilization. The company's operating margin, derived from a gross profit of BGN 567.2 million and operating income of BGN 139.1 million, suggests a healthy margin structure, though the exact margin percentage is not disclosed. Sopharma AD's revenue is primarily concentrated in the Balkans and Eastern Europe, with no disclosed segment or geographic breakdown in the provided data. The absence of segment-specific revenue data limits the ability to assess diversification or concentration risk in specific markets. The company's revenue growth trajectory is not explicitly provided, but the current FY outlook and next FY direction are not included in the input data. Historical revenue of BGN 2.64 billion provides a baseline for assessing performance, though future growth expectations remain unspecified. Sopharma AD faces a medium liquidity risk due to its current ratio of 1.3 and a negative net cash position after debt. The company's dilution risk is assessed as low, with no near-term pressure expected, and no recent dilutive events reported in the input data. No adjustments were applied to the valuation metrics, indicating that the reported figures are consistent with standard financial reporting practices. No recent events, such as filings or transcripts, are provided in the input data to inform the company's strategic or operational developments. The absence of such information limits the ability to assess the impact of external or internal factors on Sopharma AD's performance.